Overview

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study. The study will explore the long-term safety and efficacy of brivaracetam.
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Brivaracetam